Ardelyx Competitors

ChemoCentryx (NASDAQ:CCXI) and Ardelyx (NASDAQ:ARDX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation and earnings.

Profitability

This table compares ChemoCentryx and Ardelyx's net margins, return on equity and return on assets.

Volatility and Risk

ChemoCentryx has a beta of 1.7, indicating that its share price is 70% more volatile than the S&P 500. Comparatively, Ardelyx has a beta of 2.02, indicating that its share price is 102% more volatile than the S&P 500.

Institutional and Insider Ownership

80.7% of ChemoCentryx shares are held by institutional investors. Comparatively, 85.9% of Ardelyx shares are held by institutional investors. 9.3% of ChemoCentryx shares are held by insiders. Comparatively, 4.0% of Ardelyx shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares ChemoCentryx and Ardelyx's revenue, earnings per share (EPS) and valuation.

ChemoCentryx has higher revenue and earnings than Ardelyx. ChemoCentryx is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent ratings and recommmendations for ChemoCentryx and Ardelyx, as reported by MarketBeat.com.

ChemoCentryx currently has a consensus target price of $80.7778, indicating a potential upside of 74.62%. Ardelyx has a consensus target price of $14.00, indicating a potential upside of 70.94%. Given ChemoCentryx's higher probable upside, analysts plainly believe ChemoCentryx is more favorable than Ardelyx.

Summary

ChemoCentryx beats Ardelyx on 10 of the 14 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and MorphoSys (NASDAQ:MOR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Ardelyx and MorphoSys' net margins, return on equity and return on assets.

Risk and Volatility

Ardelyx has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, MorphoSys has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.

Insider and Institutional Ownership

85.9% of Ardelyx shares are owned by institutional investors. Comparatively, 3.1% of MorphoSys shares are owned by institutional investors. 4.0% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Ardelyx and MorphoSys' top-line revenue, earnings per share (EPS) and valuation.

Ardelyx has higher earnings, but lower revenue than MorphoSys. MorphoSys is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ardelyx and MorphoSys, as provided by MarketBeat.com.

Ardelyx presently has a consensus price target of $14.00, indicating a potential upside of 70.94%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than MorphoSys.

Summary

Ardelyx beats MorphoSys on 7 of the 13 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and OPKO Health (NASDAQ:OPK) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Ardelyx and OPKO Health's net margins, return on equity and return on assets.

Risk and Volatility

Ardelyx has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, OPKO Health has a beta of 1.98, suggesting that its stock price is 98% more volatile than the S&P 500.

Insider and Institutional Ownership

85.9% of Ardelyx shares are owned by institutional investors. Comparatively, 28.5% of OPKO Health shares are owned by institutional investors. 4.0% of Ardelyx shares are owned by company insiders. Comparatively, 40.9% of OPKO Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Ardelyx and OPKO Health's top-line revenue, earnings per share (EPS) and valuation.

Ardelyx has higher earnings, but lower revenue than OPKO Health. OPKO Health is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ardelyx and OPKO Health, as provided by MarketBeat.com.

Ardelyx presently has a consensus price target of $14.00, indicating a potential upside of 70.94%. OPKO Health has a consensus price target of $9.00, indicating a potential upside of 105.95%. Given OPKO Health's higher probable upside, analysts plainly believe OPKO Health is more favorable than Ardelyx.

Summary

OPKO Health beats Ardelyx on 7 of the 13 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and Karuna Therapeutics (NASDAQ:KRTX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Ardelyx and Karuna Therapeutics' net margins, return on equity and return on assets.

Risk and Volatility

Ardelyx has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Karuna Therapeutics has a beta of 2.07, suggesting that its stock price is 107% more volatile than the S&P 500.

Insider and Institutional Ownership

85.9% of Ardelyx shares are owned by institutional investors. Comparatively, 74.8% of Karuna Therapeutics shares are owned by institutional investors. 4.0% of Ardelyx shares are owned by company insiders. Comparatively, 18.1% of Karuna Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Ardelyx and Karuna Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Karuna Therapeutics has lower revenue, but higher earnings than Ardelyx. Karuna Therapeutics is trading at a lower price-to-earnings ratio than Ardelyx, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ardelyx and Karuna Therapeutics, as provided by MarketBeat.com.

Ardelyx presently has a consensus price target of $14.00, indicating a potential upside of 70.94%. Karuna Therapeutics has a consensus price target of $144.70, indicating a potential upside of 34.67%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than Karuna Therapeutics.

Summary

Karuna Therapeutics beats Ardelyx on 7 of the 12 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and Taro Pharmaceutical Industries (NYSE:TARO) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Ardelyx and Taro Pharmaceutical Industries' net margins, return on equity and return on assets.

Risk and Volatility

Ardelyx has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Taro Pharmaceutical Industries has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500.

Insider and Institutional Ownership

85.9% of Ardelyx shares are owned by institutional investors. Comparatively, 11.2% of Taro Pharmaceutical Industries shares are owned by institutional investors. 4.0% of Ardelyx shares are owned by company insiders. Comparatively, 13.8% of Taro Pharmaceutical Industries shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Ardelyx and Taro Pharmaceutical Industries' top-line revenue, earnings per share (EPS) and valuation.

Taro Pharmaceutical Industries has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Taro Pharmaceutical Industries, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ardelyx and Taro Pharmaceutical Industries, as provided by MarketBeat.com.

Ardelyx presently has a consensus price target of $14.00, indicating a potential upside of 70.94%. Taro Pharmaceutical Industries has a consensus price target of $81.00, indicating a potential upside of 7.44%. Given Ardelyx's higher probable upside, analysts plainly believe Ardelyx is more favorable than Taro Pharmaceutical Industries.

Summary

Taro Pharmaceutical Industries beats Ardelyx on 7 of the 13 factors compared between the two stocks.

Ardelyx (NASDAQ:ARDX) and Pacira BioSciences (NASDAQ:PCRX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, analyst recommendations, earnings, risk, dividends, profitability and institutional ownership.

Profitability

This table compares Ardelyx and Pacira BioSciences' net margins, return on equity and return on assets.

Risk and Volatility

Ardelyx has a beta of 2.02, suggesting that its stock price is 102% more volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 1.27, suggesting that its stock price is 27% more volatile than the S&P 500.

Insider and Institutional Ownership

85.9% of Ardelyx shares are owned by institutional investors. 4.0% of Ardelyx shares are owned by company insiders. Comparatively, 5.8% of Pacira BioSciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares Ardelyx and Pacira BioSciences' top-line revenue, earnings per share (EPS) and valuation.

Pacira BioSciences has higher revenue and earnings than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current recommendations and price targets for Ardelyx and Pacira BioSciences, as provided by MarketBeat.com.

Ardelyx presently has a consensus price target of $14.00, indicating a potential upside of 70.94%. Pacira BioSciences has a consensus price target of $77.50, indicating a potential upside of 20.25%. Given Ardelyx's stronger consensus rating and higher probable upside, analysts plainly believe Ardelyx is more favorable than Pacira BioSciences.

Summary

Pacira BioSciences beats Ardelyx on 9 of the 14 factors compared between the two stocks.